June 5, 2017 09:17 AM EDT
R&D

Mov­ing on from a tri­al dis­as­ter, Juno re­ports pos­i­tive da­ta for JCAR017 -- and a death

John Carroll

Editor & Founder

Look­ing to dis­tance it­self from a tri­al dis­as­ter that claimed 5 lives last year, Juno Ther­a­peu­tics $JUNO to­day turned to a batch of pos­i­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

We’re about to find out which RFK Jr. will show up at HHS

Astel­las shakes up man­age­ment de­spite im­pres­sive nine-month earn­ings

Il­lu­mi­na added to Chi­na's black­list fol­low­ing Biose­cure Act, tar­iffs

A service from the Financial Times